ABVX - Company ID 0001956827
Abivax S.A. trades as ABVX and has a market capitalization of $11.07 B, making it the #895 largest US-listed company by market value. This page tracks Abivax S.A. through 92 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
| Filing | Type | Filed |
|---|---|---|
| 6-K | - | 2026-05-22 |
| 6-K | - | 2026-05-20 |
| SCHEDULE 13D/A | - | 2026-05-11 |
| 6-K | - | 2026-05-07 |
| 424B7 | - | 2026-05-07 |
| 6-K | - | 2026-04-20 |
| 20-F | - | 2026-03-23 |
| 6-K | - | 2026-03-23 |
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis | Abivax
The shareholders have adopted all the resolutions proposed by the Board, and particularly the financial statements for the 2025 financial year, the compensation policy applicable to the Chairman, the Chief Executive Officer and the directors, as well as delegations granted to the Board related to financial transactions.
The information and preparatory documents for this General Meeting are made available to the Company’s shareholders in accordance with the procedures and within the time limits provided for by the applicable legal and regulatory provisions. The documents referred to in Article R.22-10-23 of the French Commercial Code are available on the Company’s website: www.abivax.com
Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares | Abivax
Abivax to Present Data on Obefazimod at Digestive Disease Week® | Abivax
The largest companies sharing Abivax S.A.'s SEC industry classification (pharmaceutical preparations).
Abivax S.A. (ABVX) has a market capitalization of $11.07 B as of 2026-07-09, ranking #895 among US-listed companies.